Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 173

1.

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group.

Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S.

Leukemia. 2017 Dec;31(12):2833-2837. doi: 10.1038/leu.2017.246. Epub 2017 Aug 14. No abstract available.

PMID:
28804126
2.

Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial.

Straka C, Liebisch P, Salwender H, Hennemann B, Metzner B, Knop S, Adler-Reichel S, Gerecke C, Wandt H, Bentz M, Bruemmendorf TH, Hentrich M, Pfreundschuh M, Wolf HH, Sezer O, Bargou R, Jung W, Trümper L, Hertenstein B, Heidemann E, Bernhard H, Lang N, Frickhofen N, Hebart H, Schmidmaier R, Sandermann A, Dechow T, Reichle A, Schnabel B, Schäfer-Eckart K, Langer C, Gramatzki M, Hinke A, Emmerich B, Einsele H.

Haematologica. 2016 Nov;101(11):1398-1406. Epub 2016 Aug 4.

3.

Granulocyte-colony stimulating factor response is superior to neutropenia duration in predicting the risk of infection after high-dose chemotherapy for myeloma and lymphoma.

Straka C, Salwender H, Schnabel B, Sandherr M, Wandt H, Hübel K, Scheid C, Metzner B, Hentrich M, Franke D, Weidenegger G, Freund M, Sezer O, Einsele H, Hinke A, Emmerich B.

Leuk Lymphoma. 2015 Feb;56(2):368-76. doi: 10.3109/10428194.2014.919631. Epub 2014 May 27.

PMID:
24794810
4.

Low temperature delays timing and enhances the cost of nitrogen fixation in the unicellular cyanobacterium Cyanothece.

Brauer VS, Stomp M, Rosso C, van Beusekom SA, Emmerich B, Stal LJ, Huisman J.

ISME J. 2013 Nov;7(11):2105-15. doi: 10.1038/ismej.2013.103. Epub 2013 Jul 4.

5.

Extramedullary multiple myeloma presenting as a pituitary mass lesion.

Dimopoulou C, Ormanns S, Eigenbrod S, Müller-Lisse U, Emmerich B, Reincke M.

Exp Clin Endocrinol Diabetes. 2012 Sep;120(8):501-4. doi: 10.1055/s-0032-1321810. Epub 2012 Jul 31.

PMID:
22851185
6.

Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study.

Bauer C, Dauer M, Saraj S, Schnurr M, Bauernfeind F, Sterzik A, Junkmann J, Jakl V, Kiefl R, Oduncu F, Emmerich B, Mayr D, Mussack T, Bruns C, Rüttinger D, Conrad C, Jauch KW, Endres S, Eigler A.

Cancer Immunol Immunother. 2011 Aug;60(8):1097-107. doi: 10.1007/s00262-011-1023-5. Epub 2011 May 6.

PMID:
21547597
7.

Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.

Hrusovsky I, Emmerich B, von Rohr A, Voegeli J, Taverna C, Olie RA, Pliskat H, Frohn C, Hess G.

Oncology. 2010;79(3-4):247-54. doi: 10.1159/000322866. Epub 2011 Mar 3.

8.

Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy.

Straka C, Sandherr M, Salwender H, Wandt H, Metzner B, Hübel K, Silling G, Hentrich M, Franke D, Schwerdtfeger R, Freund M, Sezer O, Giagounidis A, Ehninger G, Grimminger W, Engert A, Schlimok G, Scheid C, Hellmann P, Heinisch H, Einsele H, Hinke A, Emmerich B.

Blood. 2011 Feb 17;117(7):2121-8. doi: 10.1182/blood-2010-06-290080. Epub 2010 Dec 16.

9.

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia.

Eichhorst BF, Busch R, Stilgenbauer S, Stauch M, Bergmann MA, Ritgen M, Kranzhöfer N, Rohrberg R, Söling U, Burkhard O, Westermann A, Goede V, Schweighofer CD, Fischer K, Fink AM, Wendtner CM, Brittinger G, Döhner H, Emmerich B, Hallek M; German CLL Study Group (GCLLSG).

Blood. 2009 Oct 15;114(16):3382-91. doi: 10.1182/blood-2009-02-206185. Epub 2009 Jul 15.

10.
12.

Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells.

Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R.

Exp Cell Res. 2007 Oct 1;313(16):3592-603. Epub 2007 Jul 4.

PMID:
17669398
13.

Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein.

Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M, Schulze-Koops H, Pfeiffer M, Bühring HJ, Greil J, Oduncu F, Emmerich B, Fey GH, Helfrich W.

Cancer Immunol Immunother. 2008 Feb;57(2):233-46. Epub 2007 Jul 31.

PMID:
17665197
14.

First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma.

Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C, Emmerich B.

Eur J Haematol. 2007 Sep;79(3):240-3. Epub 2007 Jul 26.

PMID:
17655704
15.

Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways.

Gaul L, Mandl-Weber S, Baumann P, Emmerich B, Schmidmaier R.

J Cancer Res Clin Oncol. 2008 Feb;134(2):245-53. Epub 2007 Jul 25.

PMID:
17653574
16.

A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells.

Schwemmlein M, Stieglmaier J, Kellner C, Peipp M, Saul D, Oduncu F, Emmerich B, Stockmeyer B, Lang P, Beck JD, Fey GH.

Leukemia. 2007 Jul;21(7):1405-12. Epub 2007 May 10.

PMID:
17495978
17.

Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells.

Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R.

Anticancer Drugs. 2007 Apr;18(4):405-10.

PMID:
17351392
18.

Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.

Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, Müller MC, Schuld P, Balleisen L, Hehlmann R, Ho AD, Hochhaus A.

Cancer. 2007 Apr 15;109(8):1543-9.

19.

Evidence for cell adhesion-mediated drug resistance of multiple myeloma cells in vivo.

Schmidmaier R, Mörsdorf K, Baumann P, Emmerich B, Meinhardt G.

Int J Biol Markers. 2006 Oct-Dec;21(4):218-22.

PMID:
17177159
20.

Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy.

Eichhorst BF, Busch R, Schweighofer C, Wendtner CM, Emmerich B, Hallek M; German CLL Study Group (GCLLSG).

Br J Haematol. 2007 Jan;136(1):63-72. Epub 2006 Nov 3.

PMID:
17083342

Supplemental Content

Loading ...
Support Center